Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Scleroderma Diagnostics and Therapeutics Market by Indication (Localized, Systemic), Test Type (Blood Tests, Electrocardiogram and Echocardiogram, Imaging Techniques, Pulmonary Function Tests, Skin Biopsy), Drug Class (Calcium Channel Blockers, Chelating Agents, Corticosteroids, Endothelin Receptor Agonists, Immunosuppressive Agents, PDE-5 Inhibitors, Prostacyclin Analogues, ACE Inhibitors, H2 Blockers, Proton Pump Inhibitors) and Forecast 2022-2029

$3,000.00

Report Specifications: Market Size, Share, Growth, Trends, Forecast, Geography

Scleroderma is an autoimmune disease affecting the skin and other organs of the body. There are two main types of the disease: the localized form (called localized scleroderma, limited scleroderma, or morphea) and the systemic form (called systemic scleroderma, diffuse scleroderma, generalized scleroderma, or systemic sclerosis). Laboratory testing can identify antitopoisomerase or anticentromere antibodies. X-rays and computerized tomography (CT) scans are used to look at bone abnormalities. Thermography can detect differences in skin temperature between the lesion and normal tissue. Ultrasound and magnetic resonance imaging (MRI) can aid soft tissue assessment. There are no treatments for scleroderma itself, but organ system–specific complications are treated and relief of symptoms is often achieved with vasodilators such as calcium channel blockers, alpha blockers, serotonin receptor antagonists, angiotensin II receptor inhibitors, statins, local nitrates or iloprost. Effective treatments are available for those with severe disease, including acute kidney disease, pulmonary hypertension, lung inflammation and gastrointestinal problems.

The global scleroderma diagnostics and therapeutics market segmentation is based on indication (localized, systemic), test type (blood tests, electrocardiogram and echocardiogram, imaging techniques, pulmonary function tests, skin biopsy), drug class (calcium channel blockers, chelating agents, corticosteroids, endothelin receptor agonists, immunosuppressive agents, PDE-5 inhibitors, prostacyclin analogues, ACE inhibitors, H2 blockers, proton pump inhibitors).

The global scleroderma diagnostics and therapeutics market report provides market size ($Million 2019 to 2029), market share, trends and forecast (CAGR%, 2022 to 2029). The global scleroderma diagnostics and therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global scleroderma diagnostics and therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global scleroderma diagnostics and therapeutics market and profiled in this report include Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Corbus Pharmaceutical Holdings Inc., Cytori Therapeutics, Inc., Cumberland Pharmaceuticals, Inc., F. Hoffmann La Roche Ltd., Gilead Sciences, Inc., Merck KGaA, Pfizer, Inc., and Sanofi.

DATA INCLUDED: Scleroderma Diagnostics and Therapeutics Market Size, Scleroderma Diagnostics and Therapeutics Market Share, Scleroderma Diagnostics and Therapeutics Market Growth Rates, Scleroderma Diagnostics and Therapeutics Market Trends, and Scleroderma Diagnostics and Therapeutics Market Forecast to 2029

Market Data:

  • Global COVID-19 Impact Analysis
  • Base years for estimation: 2020 & 2021
  • Actual estimates/Historical data: 2019-2021
  • Forecast period: 2022-2029
  • Market representation: Revenue in $million and CAGR % from 2022 to 2029
  • Regional scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
  • Country scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE and others.
  • Report coverage: Revenue forecast, company share, competitive landscape, growth factors, and trends
  • 15% free customization scope: Any specific or custom requirements, which is not currently within the scope of the report, will be provided as a part of customization.

Qualitative Analysis:

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Key market opportunities
  • Market size
  • Growth trends
  • Porter’s five forces analysis
  • Market attractiveness analysis
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product portfolio
    • Strategic insights
    • Recent developments

Quantitative Analysis:

  • Market size estimates and forecast for all segments
  • Regional market size estimated and forecast for major countries
  • Company financial performance
  • Competitive landscape: Company market share analysis

Please contact us through the form below for additonal offers on individual reports.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation ($million, 2019-2029)
    • Forecast Estimation ($million and CAGR%, 2022-2029)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2027)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Key Questions Answered:
1. What are the factors driving and limiting this market, key success factors and challenges?
2. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?
3. How do markets perform between countries and regions?
4. What market segments are contributing to maximum share and greatest growth?
5. What are the product or procedure volumes by country and regions?

Actionable Insights Included:
1. Product portfolio matrix (Share vs. Growth)
2. Market attractiveness (Region vs. Growth)
3. Spot matrix (Product vs. Region)
4. Geographic distribution matrix (Share vs. Growth)

Scleroderma Diagnostics and Therapeutics Market

1. Indication
1.1. Localized
1.2. Systemic

2. Test Type
2.1. Blood Tests
2.2. Electrocardiogram and Echocardiogram
2.3. Imaging Techniques
2.4. Pulmonary Function Tests
2.5. Skin Biopsy

3. Drug Class
3.1. Calcium Channel Blockers
3.2. Chelating Agents
3.3. Corticosteroids
3.4. Endothelin Receptor Agonists
3.5. Immunosuppressive Agents
3.6. PDE-5 Inhibitors
3.7. Prostacyclin Analogues
3.8. Others (ACE Inhibitors, H2 Blockers, Proton Pump Inhibitors, etc.)

4. Geography (Region, Country)
4.1. North America (U.S., Canada)
4.2. Latin America (Brazil, Mexico, Rest of LA)
4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
4.4. Asia Pacific (Japan, China, India, Rest of APAC)
4.5. Rest of the World

5. Company Profiles
5.1. Actelion Pharmaceuticals, Inc.
5.2. Bayer AG
5.3. Boehringer Ingelheim
5.4. Corbus Pharmaceutical Holdings, Inc.
5.5. Cumberland Pharmaceuticals Inc.
5.6. Cytori Therapeutics, Inc.
5.7. F. Hoffmann La Roche Ltd.
5.8. Gilead Sciences, Inc.
5.9. Merck KGaA
5.10. Pfizer, Inc.
5.11. Sanofi

    Request ToC / Sample Report / Discount

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com